Unlike FPT155, ALPN-202 is a mutated CD80-Fc fusion protein designed to overcome checkpoint inhibitor resistance by enhancing CD28 costimulation in the tumor microenvironment while inhibiting PD-L1 and CTLA-4. Here, CD80 is linked to neoplasm.